Genzyme's Rilzabrutinib Approval Reshapes Oral ITP Treatment Options

Genzyme Corporation has secured FDA approval for WAYRILZ (rilzabrutinib), a BTK kinase inhibitor indicated for adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior therapy. Approved on August 29, 2025, the oral 400 mg twice-daily tablet enters a treatment landscape where manufacturing teams and QA functions will need to assess containment strategies and occupational exposure limits appropriate for a potent small-molecule kinase inhibitor at commercial scale.

The approval was supported by the LUNA-3 trial (NCT04562766), a randomized, placebo-controlled study enrolling 202 patients with ITP of at least three months duration, conducted across 142 sites in 26 countries spanning Asia/Pacific, Europe, North America, South America, and Australia. Sixteen percent of patients were treated in North America. Patients were randomized 2:1 to receive WAYRILZ 400 mg twice daily or placebo over a 24-week blinded treatment period. The primary endpoint assessed sustained platelet count improvement during that blinded phase. Patients without platelet response at 12 weeks were permitted to exit blinded treatment and initiate open-label WAYRILZ, a design feature that QA and regulatory teams should note when reviewing the benefit-risk data package.

Manufacturing and regulatory context: Oral kinase inhibitors in this potency class typically require robust containment engineering under 21 CFR Part 211 and alignment with ICH Q10 pharmaceutical quality system principles. Process validation programs for commercial-scale BTK inhibitor production must account for potent compound handling, cleaning validation thresholds, and cross-contamination controls, particularly in multi-product facilities. Regulatory affairs leads preparing post-approval commitments should also anticipate FDA scrutiny on process consistency data submitted as part of the NDA package.

Genzyme's WAYRILZ joins an oral ITP treatment segment that has grown with the entry of other kinase inhibitors, adding competitive pressure on manufacturers to demonstrate robust sterility assurance and process validation documentation to support commercial launch readiness. The LUNA-3 trial's multi-regional design, spanning 26 countries, also signals that post-approval variation filings across ICH and non-ICH markets will be a near-term workload for regulatory affairs teams.

Source: FDA Drug Trials Snapshots: WAYRILZ, published April 28, 2026. Approval date listed as August 29, 2025.